LANCL2

Summary

LANCL2 (LanC like glutathione S-transferase 2, HGNC:6509) is a protein-coding gene on chromosome 7p11.2, encoding LanC-like protein 2 (Q9NS86). Necessary for abscisic acid (ABA) binding on the cell membrane and activation of the ABA signaling pathway in granulocytes.

Enables phosphatidylinositol-3-phosphate binding activity; phosphatidylinositol-4-phosphate binding activity; and phosphatidylinositol-5-phosphate binding activity. Involved in negative regulation of DNA-templated transcription and positive regulation of abscisic acid-activated signaling pathway. Located in several cellular components, including cortical actin cytoskeleton; cytosol; and nucleoplasm.

Source: NCBI Gene 55915 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 83 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_018697

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:6509
Approved symbol	LANCL2
Name	LanC like glutathione S-transferase 2
Location	7p11.2
Locus type	gene with protein product
Status	Approved
Aliases	TASP
Ensembl gene	ENSG00000132434
Ensembl biotype	protein_coding
OMIM	612919
Entrez	55915

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 6 protein_coding, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay, 1 retained_intron

ENST00000254770, ENST00000452107, ENST00000466041, ENST00000476479, ENST00000486376, ENST00000872235, ENST00000872236, ENST00000916639, ENST00000952390, ENST00000952391

RefSeq mRNA: 1 — MANE Select: NM_018697 NM_018697

CCDS: CCDS5517

Canonical transcript exons

ENST00000254770 — 9 exons

Exon	Start	End
ENSE00001175819	55431226	55433737
ENSE00001243070	55365337	55366229
ENSE00003476274	55428375	55428447
ENSE00003485538	55391793	55391910
ENSE00003530655	55401174	55401320
ENSE00003586545	55425254	55425430
ENSE00003589486	55398423	55398630
ENSE00003666733	55399957	55400104
ENSE00003692203	55411907	55412089

Expression profiles

Bgee: expression breadth ubiquitous, 260 present calls, max score 93.96.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 14.6456 / max 100.4753, expressed in 1810 samples.

FANTOM5 promoters (12 alternative TSS)

Promoter ID	TPM avg	Samples expressed
78734	8.5546	1796
78728	2.8328	972
78735	2.5436	1102
78731	0.1973	116
78727	0.1215	48
78729	0.1166	59
78732	0.0971	39
78730	0.0842	35
78739	0.0514	18
78736	0.0234	1

Top tissues by expression

282 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
middle temporal gyrus	UBERON:0002771	93.96	gold quality
lateral nuclear group of thalamus	UBERON:0002736	92.74	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.86	gold quality
entorhinal cortex	UBERON:0002728	91.67	gold quality
postcentral gyrus	UBERON:0002581	91.32	gold quality
parietal lobe	UBERON:0001872	91.21	gold quality
superior frontal gyrus	UBERON:0002661	90.67	gold quality
prefrontal cortex	UBERON:0000451	90.22	gold quality
Brodmann (1909) area 23	UBERON:0013554	90.18	gold quality
sperm	CL:0000019	90.16	gold quality
endothelial cell	CL:0000115	89.50	gold quality
temporal lobe	UBERON:0001871	89.46	gold quality
frontal cortex	UBERON:0001870	88.85	gold quality
neocortex	UBERON:0001950	88.50	gold quality
cerebral cortex	UBERON:0000956	88.29	gold quality
pons	UBERON:0000988	88.29	gold quality
lateral globus pallidus	UBERON:0002476	88.27	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	88.21	gold quality
Ammon’s horn	UBERON:0001954	88.08	gold quality
superior vestibular nucleus	UBERON:0007227	88.08	gold quality
anterior cingulate cortex	UBERON:0009835	88.01	gold quality
subthalamic nucleus	UBERON:0001906	87.93	gold quality
cingulate cortex	UBERON:0003027	87.87	gold quality
telencephalon	UBERON:0001893	87.84	gold quality
male germ cell	CL:0000015	87.78	gold quality
primary visual cortex	UBERON:0002436	87.77	gold quality
amygdala	UBERON:0001876	87.65	gold quality
corpus callosum	UBERON:0002336	87.51	gold quality
left testis	UBERON:0004533	87.41	gold quality
occipital lobe	UBERON:0002021	87.28	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.41

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

83 targeting LANCL2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-493-5P	99.96	72.47	2382
HSA-MIR-381-3P	99.93	71.87	2854
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-300	99.92	71.76	2856
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-3681-5P	99.82	66.88	387
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-4307	99.82	70.45	3374

Literature-anchored findings (GeneRIF, showing 13)

• cDNA cloned and characterized. May play a role as a component of a peptide-modifying complex (PMID:11762191)
• Lanthionine synthetase components C-like 2 increases cellular sensitivity to adriamycin by decreasing the expression of P-glycoprotein through a transcription-mediated mechanism. (PMID:12566319)
• Using shotgun mass spectrometry, we found this protein differentially expressed in the dorsolateral prefrontal cortex from patients with schizophrenia. (PMID:19165527)
• Data show that lanthionine synthetase C-like protein (LANCL2) is required for abscisic acid binding on human granulocyte membranes and that LANCL2 is necessary for transduction of the ABA signal into granulocytes and rat insulinoma cells. (PMID:19667068)
• Molecular docking studies predict that ABA and other PPAR gamma agonists (e.g., rosiglitazone and pioglitazone) share a binding site on the surface of LANCL2. (PMID:20512604)
• human recombinant LANCL2 binds abscisic acid (ABA) directly and provide the first demonstration of ABA binding to a mammalian ABA receptor. (PMID:22037458)
• Data indicate that lanthionine synthetase C-like 2 (LanCL2) depletion sensitizes cells to apoptosis through down-regulating serine/threonine protein kinase Akt phosphorylation. (PMID:25273559)
• human LANCL2 is a non-transmembrane G protein-coupled receptor susceptible to hormone-induced nuclear translocation. (PMID:27222287)
• Site-directed mutagenesis (single mutant R118I, triple mutants R118I/R22I/K362I and R118I/S41A/E46I) and equilibrium binding experiments on the mutated LANCL2 proteins identified a high-affinity ABA-binding site involving R118, with a KD of 2.6nM+/-1.2nM, as determined by surface plasmon resonance. (PMID:29421190)
• Abscisic acid enriched fig extract promotes insulin sensitivity by decreasing systemic inflammation and activating LANCL2 in skeletal muscle. (PMID:32591558)
• Akt kinase LANCL2 functions as a key driver in EGFR-mutant lung adenocarcinoma tumorigenesis. (PMID:33568630)
• Identification of prognostic values defined by copy number variation, mRNA and protein expression of LANCL2 and EGFR in glioblastoma patients. (PMID:34461927)
• Abscisic acid signaling through LANCL2 and PPARgamma induces activation of p38MAPK resulting in dormancy of prostate cancer metastatic cells. (PMID:38624012)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	lancl2	ENSDARG00000045465
mus_musculus	Lancl2	ENSMUSG00000062190
rattus_norvegicus	Lancl2	ENSRNOG00000006810
drosophila_melanogaster	CG2061	FBGN0027498

Paralogs (2): LANCL1 (ENSG00000115365), LANCL3 (ENSG00000147036)

Protein

Protein identifiers

LanC-like protein 2 — Q9NS86 (reviewed: Q9NS86)

Alternative names: Testis-specific adriamycin sensitivity protein

All UniProt accessions (2): Q9NS86, H7BZ40

UniProt curated annotations — full annotation on UniProt →

Function. Necessary for abscisic acid (ABA) binding on the cell membrane and activation of the ABA signaling pathway in granulocytes.

Subunit / interactions. Interacts with an array of inositol phospholipids such as phosphatidylinositol 3-phosphate (PI3P), phosphatidylinositol 4-phosphate (PI4P) and phosphatidylinositol 5-phosphate (PI5P). PIP-binding enhances membrane association.

Subcellular location. Nucleus. Cytoplasm. Cell membrane.

Tissue specificity. Expressed in brain and testis.

Post-translational modifications. Myristoylated. Essential for membrane association.

Miscellaneous. Its exogenous expression in a sarcoma cell line decreases the expression of ABCB1 (P-glycoprotein 1) and increases cellular sensitivity to an anticancer drug (adriamycin).

Similarity. Belongs to the LanC-like protein family.

RefSeq proteins (1): NP_061167* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007822	LANC-like	Family
IPR012341	6hp_glycosidase-like_sf	Homologous_superfamily
IPR020464	LanC-like_prot_euk	Family

Pfam: PF05147

UniProt features (39 total): helix 19, turn 8, strand 4, sequence variant 2, initiator methionine 1, chain 1, region of interest 1, modified residue 1, lipid moiety-binding region 1, mutagenesis site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
6WQ1	X-RAY DIFFRACTION	2.29

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NS86-F1	92.37	0.87

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 198, 2

Mutagenesis-validated functional residues (1):

Position	Phenotype
2	loss of membrane localization and results in localization to the nucleus, particularly to the nucleoli.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 201 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_DN, MODULE_255, GOBP_CELLULAR_RESPONSE_TO_LIPID, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, MODULE_317, GOBP_CELLULAR_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_PEPTIDE_METABOLIC_PROCESS, MARTINEZ_RB1_TARGETS_UP, GOBP_HORMONE_MEDIATED_SIGNALING_PATHWAY, GOBP_CELLULAR_RESPONSE_TO_HORMONE_STIMULUS, FOSTER_TOLERANT_MACROPHAGE_UP, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GARY_CD5_TARGETS_DN

GO Biological Process (4): carbohydrate metabolic process (GO:0005975), positive regulation of abscisic acid-activated signaling pathway (GO:0009789), peptide modification (GO:0031179), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (6): ATP binding (GO:0005524), GTP binding (GO:0005525), phosphatidylinositol-5-phosphate binding (GO:0010314), phosphatidylinositol-3-phosphate binding (GO:0032266), phosphatidylinositol-4-phosphate binding (GO:0070273), protein binding (GO:0005515)

GO Cellular Component (7): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829), plasma membrane (GO:0005886), cortical actin cytoskeleton (GO:0030864), cytoplasm (GO:0005737), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
phosphatidylinositol phosphate binding	3
purine ribonucleoside triphosphate binding	2
anion binding	2
primary metabolic process	1
abscisic acid-activated signaling pathway	1
regulation of abscisic acid-activated signaling pathway	1
positive regulation of signal transduction	1
peptide metabolic process	1
DNA-templated transcription	1
regulation of DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
adenyl ribonucleotide binding	1
guanyl ribonucleotide binding	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1
membrane	1
cell periphery	1
actin cytoskeleton	1
cortical cytoskeleton	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

620 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LANCL2	EPS8	Q12929	706
LANCL2	VOPP1	Q96AW1	653
LANCL2	SEC61G	P38384	623
LANCL2	ECD	O95905	594
LANCL2	ABCB1	P08183	584
LANCL2	SEPTIN14	Q6ZU15	570
LANCL2	EGFR	P00533	543
LANCL2	VSTM2A	Q8TAG5	527
LANCL2	C7orf25	Q9BPX7	413
LANCL2	PLEKHG5	O94827	408
LANCL2	PSMD2	Q13200	406
LANCL2	ZNF713	Q8N859	398
LANCL2	SUMF2	Q8NBJ7	385
LANCL2	MAP3K13	O43283	376
LANCL2	ATP23	Q9Y6H3	371

IntAct

66 interactions, top by confidence:

A	B	Type	Score
PCGF2	CBX4	psi-mi:“MI:0914”(association)	0.840
APPBP2	LANCL2	psi-mi:“MI:0915”(physical association)	0.720
LANCL2	APPBP2	psi-mi:“MI:0915”(physical association)	0.720
TPM4	TPM3	psi-mi:“MI:0914”(association)	0.670
SIAH1	LANCL2	psi-mi:“MI:0915”(physical association)	0.560
LANCL2	TDRKH	psi-mi:“MI:0915”(physical association)	0.560
DOK2	NCK2	psi-mi:“MI:0914”(association)	0.530
MINDY3	UBB	psi-mi:“MI:0914”(association)	0.530
GSTM3	ECT2L	psi-mi:“MI:0914”(association)	0.530
MRPS18C	MRPS14	psi-mi:“MI:0914”(association)	0.530
GMFG	PRUNE1	psi-mi:“MI:0914”(association)	0.530
LANCL2	TERF2IP	psi-mi:“MI:0915”(physical association)	0.510
Eps8	LANCL2	psi-mi:“MI:0407”(direct interaction)	0.440
	TK2	psi-mi:“MI:0915”(physical association)	0.400
TERF2	LANCL2	psi-mi:“MI:0915”(physical association)	0.370
APBB1	SSPOP	psi-mi:“MI:0914”(association)	0.350
FEZ1		psi-mi:“MI:0914”(association)	0.350
PVR	QSOX1	psi-mi:“MI:0914”(association)	0.350
KCNJ5	ERI3	psi-mi:“MI:0914”(association)	0.350
GMFG	HSPA14	psi-mi:“MI:0914”(association)	0.350
OTUD5	TP53	psi-mi:“MI:0914”(association)	0.350
CIAO1	SOX1	psi-mi:“MI:0914”(association)	0.350
MAPT	SEPTIN8	psi-mi:“MI:0914”(association)	0.350
MAPT	SHTN1	psi-mi:“MI:0914”(association)	0.350

BioGRID (110): LANCL2 (Two-hybrid), LANCL2 (Affinity Capture-RNA), LANCL2 (Affinity Capture-RNA), LANCL2 (Affinity Capture-MS), LANCL2 (Affinity Capture-MS), LANCL2 (Affinity Capture-MS), LANCL2 (Affinity Capture-MS), LANCL2 (Reconstituted Complex), LANCL2 (Affinity Capture-MS), LANCL2 (Affinity Capture-MS), LANCL2 (Affinity Capture-MS), LANCL2 (Affinity Capture-MS), LANCL2 (Affinity Capture-MS), LANCL2 (Affinity Capture-MS), LANCL2 (Affinity Capture-MS)

ESM2 similar proteins: A1A5Y5, A2ACP1, B3MZN7, B3NY19, B4PYH5, B4S3A5, F1MVX2, F4IEM5, O01824, O43813, O65583, O74878, O89112, O94710, P56523, Q08DA5, Q25566, Q26609, Q28901, Q28D40, Q290Z2, Q29HZ1, Q2KNB7, Q55D85, Q5JVF3, Q5SRH9, Q5U3P0, Q623S8, Q6CUZ3, Q7K3B9, Q7K3M5, Q80VY9, Q8VYB2, Q8VZQ6, Q90ZL2, Q94263, Q9FJN7, Q9FKS0, Q9H6R0, Q9JJK2

Diamond homologs: F1MVX2, F4IEM5, O43813, O89112, Q29HZ1, Q6ZV70, Q8CD19, Q8VZQ6, Q90ZL2, Q9JJK2, Q9NS86, Q9QX69, Q9Y0Y7, Q9FJN7

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 77 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Signaling by ALK fusions and activated point mutants	6	18.4×	4e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

83 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	65
Likely benign	3
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

1929 predictions. Top by Δscore:

Variant	Effect	Δscore
7:55391783:T:A	acceptor_gain	1.0000
7:55391784:G:A	acceptor_gain	1.0000
7:55391789:TCA:T	acceptor_loss	1.0000
7:55391791:A:AG	acceptor_gain	1.0000
7:55391792:G:GA	acceptor_gain	1.0000
7:55391792:GA:G	acceptor_gain	1.0000
7:55391792:GAT:G	acceptor_gain	1.0000
7:55391792:GATC:G	acceptor_gain	1.0000
7:55391792:GATCA:G	acceptor_gain	1.0000
7:55398631:G:GG	donor_gain	1.0000
7:55401169:TGTA:T	acceptor_loss	1.0000
7:55401171:TAGG:T	acceptor_loss	1.0000
7:55401173:G:A	acceptor_loss	1.0000
7:55401173:GGTA:G	acceptor_gain	1.0000
7:55410025:A:T	donor_gain	1.0000
7:55411894:T:TA	acceptor_gain	1.0000
7:55411898:T:A	acceptor_gain	1.0000
7:55411902:TAAA:T	acceptor_loss	1.0000
7:55411903:A:AG	acceptor_gain	1.0000
7:55411903:AAAGC:A	acceptor_loss	1.0000
7:55411904:A:G	acceptor_gain	1.0000
7:55411904:AAG:A	acceptor_loss	1.0000
7:55411904:AAGCC:A	acceptor_gain	1.0000
7:55411905:A:C	acceptor_loss	1.0000
7:55411905:A:G	acceptor_gain	1.0000
7:55411905:AGCC:A	acceptor_gain	1.0000
7:55411905:AGCCG:A	acceptor_gain	1.0000
7:55411906:G:GT	acceptor_gain	1.0000
7:55411906:GC:G	acceptor_gain	1.0000
7:55411906:GCC:G	acceptor_gain	1.0000

AlphaMissense

2903 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:55391902:G:A	G105D	1.000
7:55401255:T:A	W254R	1.000
7:55401255:T:C	W254R	1.000
7:55401270:T:C	Y259H	1.000
7:55401285:C:G	H264D	1.000
7:55401287:T:A	H264Q	1.000
7:55401287:T:G	H264Q	1.000
7:55401289:G:A	G265D	1.000
7:55412039:T:A	W320R	1.000
7:55412039:T:C	W320R	1.000
7:55412042:T:C	C321R	1.000
7:55412043:G:A	C321Y	1.000
7:55412043:G:T	C321F	1.000
7:55412044:C:G	C321W	1.000
7:55412045:C:G	H322D	1.000
7:55412047:C:A	H322Q	1.000
7:55412047:C:G	H322Q	1.000
7:55425331:G:C	K362N	1.000
7:55425331:G:T	K362N	1.000
7:55425332:G:C	G363R	1.000
7:55425344:T:C	C367R	1.000
7:55425345:G:A	C367Y	1.000
7:55425346:C:G	C367W	1.000
7:55425347:C:G	H368D	1.000
7:55425349:T:A	H368Q	1.000
7:55425349:T:G	H368Q	1.000
7:55425350:G:T	G369W	1.000
7:55425351:G:A	G369E	1.000
7:55428447:G:C	G420R	1.000
7:55428447:G:T	G420C	1.000

dbSNP variants (sampled 300 via entrez): RS1000053898 (7:55413957 C>G), RS1000092055 (7:55375927 A>G), RS1000116584 (7:55391269 C>T), RS1000129356 (7:55410375 G>A), RS1000139555 (7:55423171 G>A), RS1000163669 (7:55379568 TCTG>T), RS1000326479 (7:55385724 T>C), RS1000366439 (7:55365347 G>T), RS1000435192 (7:55379906 T>C,G), RS1000452357 (7:55405030 G>A), RS1000460532 (7:55420552 G>A), RS1000512149 (7:55422019 A>G), RS1000517165 (7:55391572 T>A), RS1000552870 (7:55382071 T>C), RS1000578055 (7:55397410 G>A)

Disease associations

OMIM: gene MIM:612919 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST002927_19	Mercury levels	3.000000e-06
GCST004033_17	QRS interval (sulfonylurea treatment interaction)	6.000000e-08
GCST007622_2	Impulsivity	1.000000e-06
GCST009306_11	Spatial processing	6.000000e-06
GCST009391_1434	Metabolite levels	8.000000e-06

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0007922	response to sulfonylurea
EFO:0006946	behavioural disinhibition measurement
EFO:0008354	cognitive function measurement
EFO:0010408	triacylglycerol 50:1 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL3351212 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 341 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL4788758	OMILANCOR	2	341

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: other protein — Abscisic acid receptor complex

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
abscisic acid	Binding	7.96	pKd
omilancor	Binding	5.11	pKd

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.18	IC50	6.56	nM	CHEMBL3355910
5.11	Kd	7700	nM	OMILANCOR

PubChem BioAssay actives

2 with measured affinity, of 19 total; 2 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2Z,4E)-5-(2-hydroxy-1,3,3-trimethyl-5-oxo-7-oxabicyclo[4.1.0]heptan-2-yl)-3-methylpenta-2,4-dienoic acid	1176049: Inhibition of ABA binding to LANCL2 (unknown origin)	ic50	0.0066	uM
[4-[6-(1H-benzimidazol-2-yl)pyridine-2-carbonyl]piperazin-1-yl]-[6-(1H-benzimidazol-2-yl)-2-pyridinyl]methanone	1714416: Binding affinity to LANCL2 (unknown origin) by surface plasmon resonance analysis	kd	7.7000	uM

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression	5
Cisplatin	affects cotreatment, decreases expression, affects expression	3
bisphenol A	decreases expression, increases expression	2
trichostatin A	affects expression, decreases expression	2
Smoke	decreases expression, increases abundance	2
GSK-J4	decreases expression	1
bisphenol F	increases expression	1
methylmercuric chloride	decreases expression	1
sodium arsenite	increases expression	1
tetrabromobisphenol A	decreases expression	1
beta-methylcholine	affects expression	1
CGP 52608	affects binding, increases reaction	1
entinostat	decreases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	decreases expression	1
ICG 001	increases expression	1
bisphenol B	increases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
bisphenol S	increases expression	1
jinfukang	affects cotreatment, decreases expression	1
bisphenol AF	increases expression	1
Decitabine	affects expression	1
Air Pollutants	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation, decreases methylation	1
Enzyme Inhibitors	decreases activity, increases O-linked glycosylation	1
Ivermectin	decreases expression	1
Mercury	decreases expression	1
Methotrexate	decreases expression	1

ChEMBL screening assays

8 unique, capped per target: 8 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3374271	Binding	Inhibition of ABA binding to LANCL2 (unknown origin)	Synthesis, structural characterization and effect on human granulocyte intracellular cAMP levels of abscisic acid analogs. — Bioorg Med Chem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.